CN103391786B - 作为抗糖尿病肽的载脂蛋白a-iv - Google Patents

作为抗糖尿病肽的载脂蛋白a-iv Download PDF

Info

Publication number
CN103391786B
CN103391786B CN201280005394.9A CN201280005394A CN103391786B CN 103391786 B CN103391786 B CN 103391786B CN 201280005394 A CN201280005394 A CN 201280005394A CN 103391786 B CN103391786 B CN 103391786B
Authority
CN
China
Prior art keywords
apoa
polypeptide
mice
use according
apolipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280005394.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103391786A (zh
Inventor
P·特索
S·戴维森
S·伍兹
王飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of CN103391786A publication Critical patent/CN103391786A/zh
Application granted granted Critical
Publication of CN103391786B publication Critical patent/CN103391786B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201280005394.9A 2011-01-19 2012-01-19 作为抗糖尿病肽的载脂蛋白a-iv Expired - Fee Related CN103391786B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434196P 2011-01-19 2011-01-19
US61/434,196 2011-01-19
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide

Publications (2)

Publication Number Publication Date
CN103391786A CN103391786A (zh) 2013-11-13
CN103391786B true CN103391786B (zh) 2016-06-22

Family

ID=45755499

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280005394.9A Expired - Fee Related CN103391786B (zh) 2011-01-19 2012-01-19 作为抗糖尿病肽的载脂蛋白a-iv

Country Status (13)

Country Link
US (2) US9051394B2 (enExample)
EP (1) EP2665485B1 (enExample)
JP (1) JP2014504601A (enExample)
KR (1) KR20140071272A (enExample)
CN (1) CN103391786B (enExample)
AU (1) AU2012207301B2 (enExample)
CA (1) CA2823712A1 (enExample)
EA (1) EA028218B1 (enExample)
ES (1) ES2620404T3 (enExample)
IL (1) IL227207B (enExample)
MX (1) MX342020B (enExample)
SG (1) SG191992A1 (enExample)
WO (1) WO2012100010A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786584C (en) * 2010-03-12 2017-07-18 Exxonmobil Upstream Research Company Dynamic grouping of domain objects via smart groups
CN103391786B (zh) 2011-01-19 2016-06-22 辛辛那提大学 作为抗糖尿病肽的载脂蛋白a-iv
CA2860782A1 (en) 2012-01-19 2013-07-25 Patrick Tso Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668645A (zh) * 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
WO2010060387A1 (zh) * 2008-11-28 2010-06-03 中国医学科学院药物研究所 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
WO1994027629A1 (en) 1993-05-28 1994-12-08 Merck & Co., Inc. Method to control appetite and treat obesity
WO2001077124A2 (en) * 2000-04-05 2001-10-18 Genaissance Pharmaceuticals, Inc. Haplotypes of the apoa4 gene
US20100267052A1 (en) * 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
AU2009226246A1 (en) * 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103391786B (zh) 2011-01-19 2016-06-22 辛辛那提大学 作为抗糖尿病肽的载脂蛋白a-iv
CA2860782A1 (en) 2012-01-19 2013-07-25 Patrick Tso Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668645A (zh) * 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
WO2010060387A1 (zh) * 2008-11-28 2010-06-03 中国医学科学院药物研究所 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
小腸粘膜の生理と糖尿病治療;奥村利勝等;《日薬理誌》;20020731;第120卷;19-31 *

Also Published As

Publication number Publication date
AU2012207301A1 (en) 2013-08-01
AU2012207301A2 (en) 2015-03-26
US9051394B2 (en) 2015-06-09
ES2620404T3 (es) 2017-06-28
MX342020B (es) 2016-09-08
MX2013008374A (es) 2013-12-06
US20150252095A1 (en) 2015-09-10
EA201391063A1 (ru) 2013-12-30
JP2014504601A (ja) 2014-02-24
US9266941B2 (en) 2016-02-23
EP2665485B1 (en) 2017-01-11
US20140005107A1 (en) 2014-01-02
AU2012207301A8 (en) 2013-08-29
EA028218B1 (ru) 2017-10-31
EP2665485A1 (en) 2013-11-27
AU2012207301B2 (en) 2016-05-19
SG191992A1 (en) 2013-08-30
WO2012100010A1 (en) 2012-07-26
IL227207B (en) 2019-09-26
CA2823712A1 (en) 2012-07-26
CN103391786A (zh) 2013-11-13
KR20140071272A (ko) 2014-06-11

Similar Documents

Publication Publication Date Title
CN103391786B (zh) 作为抗糖尿病肽的载脂蛋白a-iv
CN106715466B (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物
ES3011982T3 (en) Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN104066436B (zh) 使用非糖基化载脂蛋白a‑iv治疗糖尿病的方法
CN107921085A (zh) 用于治疗衰老相关病症的方法和组合物
JP2007519642A (ja) 血糖値を調節するためのｇｌｐ−１アゴニストとガストリンとの合わせた使用
JP2008543878A5 (enExample)
TWI788323B (zh) Apoc-ii擬肽
AU2012385960B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
JP2009508847A (ja) 栄養状態、認知および生存を改善するための化合物
CN1938334A (zh) Glp－1激动剂和胃泌素化合物的联合使用
JP2019520341A (ja) 代謝疾患を治療する組成物と方法
KR20220027204A (ko) 글루카곤 및 glp-1 공동작용제 펩타이드의 제약 조성물
US20250114431A1 (en) Compound, composition and methods for lowering circulating glucose
US20150197550A1 (en) Therapeutic Uses of Dogfish Glucagon and Analogues Thereof
EA042134B1 (ru) МИМЕТИЧЕСКИЕ ПЕПТИДЫ apoC-II
HK1247102B (zh) 用於治疗衰老相关病症的方法和组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160622

Termination date: 20180119